262 related articles for article (PubMed ID: 6776227)
1. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M
J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.
Uyttenhove C; Van Snick J; Boon T
J Exp Med; 1980 Nov; 152(5):1175-83. PubMed ID: 6776226
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.
Maryanski JL; Marchand M; Uyttenhove C; Boon T
Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.
Maryanski JL; Szpirer J; Szpirer C; Boon T
Somatic Cell Genet; 1983 May; 9(3):345-57. PubMed ID: 6407125
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
Maryanski JL; Van Snick J; Cerottini JC; Boon T
Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens.
Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T
Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay.
Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T
Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137
[TBL] [Abstract][Full Text] [Related]
9. Tumour cell variants with increased immunogenicity obtained by mutagen treatment.
Boon T; Maryanski J
Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855
[TBL] [Abstract][Full Text] [Related]
10. Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815.
Marchand M; Caspar P; Boon T
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1529-37. PubMed ID: 6196202
[TBL] [Abstract][Full Text] [Related]
11. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
Uyttenhove C; Maryanski J; Boon T
J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879
[TBL] [Abstract][Full Text] [Related]
12. Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele.
Szikora JP; Van Pel A; Brichard V; André M; Van Baren N; Henry P; De Plaen E; Boon T
EMBO J; 1990 Apr; 9(4):1041-50. PubMed ID: 2108859
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.
De Plaen E; Lurquin C; Van Pel A; Mariamé B; Szikora JP; Wölfel T; Sibille C; Chomez P; Boon T
Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2274-8. PubMed ID: 3127830
[TBL] [Abstract][Full Text] [Related]
14. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
15. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
Germain RN; Williams RM; Benacerraf B
Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
[TBL] [Abstract][Full Text] [Related]
16. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse.
Wolf JE; Faanes RB; Choi YS
J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213
[TBL] [Abstract][Full Text] [Related]
17. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cell responses to a syngeneic tumour: conditions for primary activation in vitro.
Warren HS; Woolnough JA; Lafferty KJ
Aust J Exp Biol Med Sci; 1978 Apr; 56(2):247-51. PubMed ID: 98140
[TBL] [Abstract][Full Text] [Related]
19. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
Hines DL
Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
[TBL] [Abstract][Full Text] [Related]
20. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
